Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/26
A61K-038/28
A61K-038/16
A61K-038/00
C07K-005/00
출원번호
UP-0913309
(2004-08-06)
등록번호
US-RE41288
(2010-05-20)
발명자
/ 주소
Coolidge, Thomas R.
Ehlers, Mario R. W.
출원인 / 주소
Amylin Pharmaceuticals, Inc.
인용정보
피인용 횟수 :
12인용 특허 :
9
초록▼
It has now been discovered that GLP-1 treatment after acute stroke or hemorrhage, preferably intravenous administration, can be an ideal treatment because it provides a means for optimizing insulin secretion, increasing brain anabolism, enhancing insulin effectiveness by suppressing glucagon, and ma
It has now been discovered that GLP-1 treatment after acute stroke or hemorrhage, preferably intravenous administration, can be an ideal treatment because it provides a means for optimizing insulin secretion, increasing brain anabolism, enhancing insulin effectiveness by suppressing glucagon, and maintaining euglycemia or mild hypoglycemia with no risk of severe hypoglycemia.
대표청구항▼
What is claimed is: 1. A method of increasing insulinotropic response in ischemia treating reperfusion-injured brain cells after an ischemic event comprising administering a composition containing glucagon-like peptide-1 (GLP-1) and a pharmaceutical carrier for a time sufficient and under conditi
What is claimed is: 1. A method of increasing insulinotropic response in ischemia treating reperfusion-injured brain cells after an ischemic event comprising administering a composition containing glucagon-like peptide-1 (GLP-1) and a pharmaceutical carrier for a time sufficient and under conditions effective to increase insulinotropic response which produces insulin, with the produced insulin being neuroprotective by direct neurotropic effects and by controlling stroke-related hyperglycemia treat reperfusion injury. 2. The method of claim 1 wherein the pharmaceutical carrier is selected from the group consisting of saline, buffered saline, dextrose, water, glycerol, ethanol, lactose, phosphate, mannitol, arginine, treholose, and combinations mixtures thereof. 3. The method of claim 1 wherein the administration commences within 4 hours of an ischemic event. 4. The method of claim 1 wherein the administration of the composition is continuous and intravenously at 0.1 pmol/kg/min to 10 pmol/kg/min. 5. The method of claim 1 wherein the administration of the composition is a bolus subcutaneous injection at 0.1 nmol/kg to 75 nmol/kg. 6. The method of claim 1 wherein the administration is by a method selected from the group consisting of intravenous, intramuscular, intraperitoneal, subcutaneous or micropressure injection, deep lung insufflation, external or implant pump, depot injection, and other sustained release mechanisms, buccal, and other cross skin and membrane mechanisms and patch sustained release delivery mechanisms. 7. The method of claim 1 wherein the composition is administered intravenously at a dose of 0.1 pmol/kg/min up to 10 pmol/kg/min. 8. The method of claim 7 1 further comprising concurrent administration of glucose. 9. The method of claim 7 1 further comprising concurrent administration of an oxygen scavenger. 10. A method of increasing insulinotropic response in ischemia injured brain cells comprising administering to an individual in need of such treatment a dose of 0.1 pmol/kg/min to 10 pmol/kg/min of a composition containing glucagon-like peptide-1 (GLP-1) and a pharmaceutical carrier for a time sufficient and under conditions effective to increase insulinotropic response which produces insulin, with the produced insulin being neuroprotective by direct neurotropic effects and by controlling stroke-related hyperglycemia. 11. The method of claim 1 further comprising administering a thrombolytic agent. 12. A method of treating or ameliorating injury to brain cells in a subject following reperfusion after a period of ischemia comprising administering a composition comprising a glucagon-like peptide-1 (GLP-1) mimetic and a pharmaceutical carrier for a time sufficient and under conditions effective to treat or ameliorate said injury. 13. The method of claim 12 wherein said GLP-1 mimetic is GLP-1 (1-37), GLP-1(1-36) amide, GLP-1(7-37), GLP-1(7-36) amide or mixtures thereof. 14. The method of claim 12 wherein said GLP-1 mimetic is an exendin. 15. The method of claim 14 wherein said exendin is exendin-3. 16. The method of claim 14 wherein said exendin is exendin-4. 17. The method of claim 12 wherein said subject is not hyperglycemic. 18. A method of treating or ameliorating reperfusion injury to brain cells following stroke in a subject in need thereof, comprising administering a composition comprising an exendin to said subject for a time sufficient and under conditions effective to treat or ameliorate the reperfusion injury. 19. The method of claim 18 wherein said exendin is exendin-3. 20. The method of claim 18 wherein said exendin is exendin-4. 21. The method of claim 18 wherein said subject is not hyperglycemic. 22. The method of claim 18 wherein said stroke is ischemic. 23. The method of claim 18 wherein said stroke is hemorrhagic. 24. The method of claim 18 further comprising administering a thrombolytic agent. 25. The method of claim 18 wherein the administration is by a method selected from the group consisting of intravenous, intramuscular, interperitoneal, subcutaneous or micropressure injection, deep lung insufflation, depot injection, buccal, patch, and sustained release delivery methods. 26. A method of treating or ameliorating injury to brain cells in a subject following a period of ischemia comprising administering a composition comprising an exendin and a pharmaceutical carrier. 27. The method of claim 27 wherein said exendin is exendin-4. 28. The method of claim 27 further comprising administering a thrombolytic agent. 29. The method of claim 27 wherein the injury is caused by reperfusion.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (9)
Johnson William T. (Indianapolis IN) Yakubu-Madas Fatima E. (Indianapolis IN), Biologically active fragments of glucagon-like insulinotropic peptide.
DiPerna, Paul M.; Brown, David; Rosinko, Mike; Kincade, Dan; Michaud, Michael; Nadworny, John; Kruse, Geoffrey A.; Ulrich, Thomas R., Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
DiPerna, Paul M.; Brown, David; Rosinko, Mike; Kincade, Dan; Michaud, Michael; Nadworny, John; Kruse, Geoffrey A.; Ulrich, Thomas R., Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
Verhoef, Erik T.; DiPerna, Paul M.; Rosinko, Mike; Williamson, Mark; Kruse, Geoffrey A.; Ulrich, Thomas R.; Lamb, Phil; Saint, Sean; Michaud, Michael; Trevaskis, William, Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.